Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog

Blog Article

Insulinoma is a rare pancreatic neuroendocrine tumor.Overproduction of insulin and associated hypoglycemia are hallmark features of this disease.Diagnosis can be made through demonstration of hypoglycemia and elevated plasma levels of insulin or C-Peptide.

Metastatic In Ground Product (Cleaners) disease can be detected through computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT.Somatostatin receptor scintigraphy can be used not only to document metastatic disease but also as a predictive marker of the benefit from therapy with radiolabeled somatostatin analog.Unresectable metastatic insulinomas may present as a major therapeutic challenge for the treating physician.

When feasible, resection is the mainstay of treatment.Prevention of hypoglycemia is a crucial goal of therapy for unresectable/metastatic tumors.Diazoxide, hydrochlorothiazide, glucagon, and intravenous glucose infusions have 5 Piece Queen Louvered Panel Bedroom been used for glycemic control yielding temporary and inconsistent results.

Sandostatin and its long-acting depot forms have occasionally been used in the treatment of Octreoscan-positive insulinomas.Herein, we report a case of metastatic insulinoma with very difficult glycemic control successfully treated with the radiolabeled somatostatin analog lutetium (177LU).